WATERTOWN -
The event will feature presentations and discussions with:
Tom Wilkinson, MA (Cantab), MBBS, PhD, FRCP, FERS - Professor of Respiratory Medicine and Associate Dean,
The event will be led by
Event details are as follows
Respiratory Syncytial Virus: The Evolving Treatment Landscape
Date and Time:
Webcast Link: Register
A webcast of the event will be available on the investor relations page of the
About
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta's research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET (
Contact:
Tel: 617-744-3848
Email: jviera@enanta.com
(C) 2023 Electronic News Publishing, source